Eye injection for age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new eye injection to treat wet age-related macular degeneration (AMD), a condition that can cause blurry vision. The study checks if the injection is safe and helpful for people with active AMD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 50 years or older
- Have wet AMD with active signs of bleeding, swelling, or fluid in the eye
- Your vision in the study eye should be between 20/40 and 20/400
- Have had some improvement with standard anti-VEGF injections (like Eylea or Avastin) in the past 6 months
- Have no other eye conditions that could affect your vision or eye exams
- Be willing to use contraception and not plan to have children during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This trial tests a new gene therapy called EXG202 for wet age-related macular degeneration, a common cause of vision loss. The goal is to see if a single treatment can safely reduce the need for frequent eye injections.
This study tests an investigational drug given as an eye injection to treat wet age-related macular degeneration (AMD) in people who have not been treated before. The goal is to see if it can help improve vision and reduce the need for frequent injections.
This study tests a new medicine given as an eye injection to treat wet age-related macular degeneration (AMD), a condition that causes blurry or lost vision. The treatment aims to improve vision by targeting abnormal blood vessels in the eye.
This trial tests a new eye drop called NT-101 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if the drops can improve vision and reduce fluid in the eye, possibly as a less invasive alternative to injections.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
Hear when a new Wet Age-related Macular Degeneration (wAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.